Skip to main content
Erschienen in: European Journal of Nutrition 5/2016

Open Access 15.08.2015 | Original Contribution

Chronic black tea extract consumption improves endothelial function in ovariectomized rats

verfasst von: Fung Ping Leung, Lai Ming Yung, Ching Yuen Ngai, Wai San Cheang, Xiao Yu Tian, Chi Wai Lau, Yang Zhang, Jian Liu, Zhen Yu Chen, Zhao-Xiang Bian, Xiaoqiang Yao, Yu Huang

Erschienen in: European Journal of Nutrition | Ausgabe 5/2016

Abstract

Purpose

Menopause escalates the risk of cardiovascular diseases in women. There is an unmet need for better treatment strategy for estrogen-deficiency-related cardiovascular complications. Here we investigated the impact of chronic black tea extract (BT) consumption on cardiovascular function and lipid metabolism using a rat model of estrogen deficiency.

Methods

Female Sprague–Dawley rats were ovariectomized (OVX) and treated with BT (15 mg/kg/day, 4 weeks; active ingredients: theaflavins) or estrogen (E2) treatment for 4 weeks. Serum was collected for measuring cholesterol, triacylglycerol and estradiol levels. Changes in vascular reactivity were examined. The protein levels of NADPH oxidases were assessed by Western blotting. Reactive oxygen species (ROS) level was measured using dihydroethidium fluorescence imaging. The concentrations of cGMP were measured using ELISA kit.

Results

Aortic rings from control, BT-treated and E2-treated OVX rats exhibited a greater increase in Phe-induced contraction after inhibition of NO synthase compared with those from OVX rats. ACh-induced endothelium-dependent relaxations were augmented in aortae and renal arteries in BT/E2-treated OVX rats than in OVX rats. BT/E2 treatment improved flow-mediated dilatation in small mesenteric resistance arteries of OVX rats. BT/E2 treatment restored the eNOS phosphorylation level and reversed the up-regulation of NADPH oxidases and ROS overproduction in OVX rat aortae. ACh-stimulated cGMP production was significantly elevated in the aortae from BT- and E2-treated rats compared with those from OVX rats. BT/E2 treatment reduced circulating levels of total cholesterol.

Conclusions

The present study reveals the novel benefits of chronic BT consumption to reverse endothelial dysfunction and favorably modifying cholesterol profile in a rat model of estrogen deficiency and provides insights into developing BT as beneficial dietary supplements for postmenopausal women.

Introduction

Cardiovascular disease (CVD) risk rises with age, but for women symptoms can become more manifest after the onset of menopause. In this natural state of estrogen deficiency, hormone replacement therapy (HRT) is effective in reducing the incidence of coronary heart disease as well as in mortality from CVD [1, 2]. However, HRT is also associated with an increased risk of cancers and cardiovascular events, such as venous thromboembolism and stroke [35]. Moreover, the results of two large randomized prospective findings disprove the claims of cardiovascular benefits of HRT based on observational studies. The Heart and Estrogen/Progestin Replacement Study was a randomized clinical trial designed to test the efficacy of HRT in the secondary prevention of coronary heart diseases. The results indicated that treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not lower the overall rate of coronary heart disease events in postmenopausal women with established coronary disease. In contrast, the treatment increased the rate of thromboembolic events and gall bladder disease [6]. Another prospective study of primary prevention of CVD, named as the Women’s Health Initiative (WHI), was stopped in early phase, as it was demonstrated that overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women [7]. Another study evaluated the results of the therapeutic arm of the WHI investigating the isolated use of conjugated estrogens versus placebo among hysterectomized postmenopausal women. There was an increased risk of cerebral vascular accident, but a reduced risk of hip fracture and null effect on the incidence of CVD, as well as potential reduction in the incidence of breast cancer. Overall, the risk–benefit index was neutral [8].
Tea, the most popular beverage worldwide, is consumed in three basic forms: green tea, black tea and oolong tea. Recently, there has been a mounting interest in understanding the cardiovascular and metabolic benefits of polyphenolic flavonoids in tea, which can be used as health supplement. Compelling evidence in human and murine models also suggests various cardioprotective benefits of consuming tea or tea polyphenols under pathological conditions, e.g. hypertension, atherosclerosis, diabetics, hypercholesterolemia, obesity, and are attributed to antioxidative, anti-thrombogenic, anti-inflammatory, hypotensive and hypocholesterolemic properties of tea polyphenols [9, 10]. Yung et al. [11] also discussed the cardiovascular benefits of tea polyphenols in four related fields (1) vasorelaxant effect; (2) protective effect against endothelial dysfunction; (3) antioxidant effect and (4) hypolipidemic effect [11]. A recent meta-analysis suggests that daily consumption of black tea equaling three cups per day could prevent the onset of ischemic stroke [12]. Black tea is equally potent as green tea in promoting cardiovascular health, as theaflavins and thearubigins predominantly counterbalance the lack of catechins in black tea [13]. Overall, tea represents a promising tool for the prevention of cardiovascular complications. In the present study, we test the hypothesis that black tea consumption ameliorates endothelial dysfunction during estrogen deficiency.

Methods

Animal treatment and artery preparation

All the experimental protocol was approved by the institutional animal care and use committee and was consistent with the Guide for the Care and Use of laboratory Animals published by the National Institutes of Health. Adult female Sprague–Dawley rats (3 months old, weighing 200–230 g) were purchased from the Laboratory Animal Service Center, Chinese University of Hong Kong. Rats were anesthetized using sodium pentobarbital (40 mg/kg body weight, intraperitoneal injection), ovariectomized via a mid-abdominal route. Three months after ovariectomy, the rats were randomly assigned into three experimental groups: (1) OVX, ovariectomized rats; (2) OVX + BT, ovariectomized rats receiving daily administration of black tea extract (BT) (Quality Phytochemicals LLC; Product code: QP-Black tea extract; Source: Camellia sinensis O. Ktze; Active ingredients (assay by HPLC): Theaflavins 70 %) at 15 mg kg-1 day-1 by gastric gavage for 4 weeks; and (3) OVX + E2, ovariectomized rats with estrogen (E2) treatment for 4 weeks, by inserting a 17β-estradiol pellet (0.5 mg/pellet, Innovative Research of America) into the dorsal subcutaneous pockets [14]. The sham-operated rats served as controls (Control). Black tea extract administration was initiated at the fourth week after ovariectomy. The animals were killed at the age of 7 months. All animals were housed under conditions of controlled temperature (23 ± 2 °C) and humidity (60 %) with 12-h light/dark cycles.

Blood collection, measurement of cholesterol profiles, and serum estrogen

At the end of chronic treatment, the rats were euthanized by CO2 suffocation and sera were collected for analysis of levels of estrogen and lipids. Hearts and uteri were dissected free of surrounding fat pads and then weighed. Serum levels of total cholesterol (Sigma 352-20), triacylglycerols (Sigma 336-20), and HDL cholesterol were determined using enzymatic kits as described previously [14]. Serum 17β-estradiol levels were measured using an estradiol EIA Kit (Cayman Chemical).

Artery preparation

The thoracic aorta was dissected and cleaned of adhering connective tissue in ice-cold and oxygenated Krebs-Henseleit solution containing (mM): 119 NaCl, 4.7 KCl, 2.5 CaCl2, 1 MgCl2, 25 NaHCO3, 1.2 KH2PO4, and 11 d-glucose. Each aorta was cut into several ring segments (3 mm in length) for parallel studies, and each experiment was performed on rings obtained from different rats. The fresh aortic ring was suspended between two stainless steel hooks in a 10-mL organ bath filled with Krebs solution. Bathing solution was continuously bubbled with 95 % O2 and 5 % CO2 and maintained at 37 °C (pH of 7.3–7.5). An optimal baseline tone of 2.5 g was applied to all rings. The renal interlobar arteries were cleaned of adjacent renal tissue, dissected to small segments, and placed in ice-cold Krebs solution. Arteries were prepared, and changes of isometric tension were recorded in myograph.

Functional studies by organ bath

In the first series of experiments, two consecutive concentration–response curves to Phe were obtained in rings with endothelium. After the first concentration–response curve, rings were incubated with 100 μM NG-nitro-l-arginine methyl ester (L-NAME) or 3 μM 1H- [1, 2, 4] oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) for 30 min. Contractions were determined as percentages of Emax obtained for the first concentration–response curve. At the end of each experiment, rings were collected, dried and weighed. Agonist-induced active tone was expressed as mN/mg tissue dry weight. In the second set of experiments, acetylcholine (ACh) was used to induce endothelial-dependent relaxation in phenylephrine (Phe, 1 μM)-contracted rings. The relaxant effects of sodium nitroprusside (SNP) were also examined. Each dilator was added cumulatively to bathing solution in 1-min intervals.

Functional study by wire myograph

Renal interlobar arteries were initially stretched to an optimal resting tension (renal arteries: 3 mN) and equilibrated at 37 °C for 60 min before the start of experiments [14]. Rings were contracted with 60 mmol/L KCl and rinsed in Krebs solution. Each ring was then contracted by phenylephrine (Phe, 0.3 μM). Once a sustained tension was reached, ACh (3 nM-10 µM) was added cumulatively to evoke endothelium-dependent relaxations (EDRs).

Flow-mediated dilatation (FMD) in pressure myograph

The third-order rat mesenteric artery (external diameter: 280–350 μm) was dissected free of surrounding adipose tissue and was cannulated between two glass cannulas in a chamber filled with 10 mL of oxygenated Krebs solution kept as previously described [15, 16]. The intraluminal pressure and vessel diameter were monitored by a light-inverted microscope (Zeiss Axiovert 40 microscope, model 11 P) with video camera, and the Myo-View software (Danish Myo Technology). Under no-flow condition, the artery segment was subjected to stepwise increment of 20 mmHg in intraluminal pressure from 20 to 80 mmHg at 5-min intervals at 37 °C and 3 μM phenylephrine (Phe) was added to induce vasoconstriction after the vessel’s diameter stabilized. FMD was triggered by pressure change that equals ~15 dynes/cm2 shear stress. Passive dilation was tested at the end of experiment in the Ca2+-free Krebs solution with 2 mM EGTA. FMD was calculated as the percentage of passive dilation: (flow-induced dilation—Phe tone)/(passive dilation—Phe tone).

Western blotting analysis

Aortae were homogenized in tissue homogenizer on ice and centrifuged to collect supernatants. Protein samples (50 µg) were separated with 10 % SDS–PAGE and transferred to a nitrocellulose immobilon-P polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA). Primary antibodies against eNOS (1:500, BD Transduction Laboratories), phosphorylated eNOS at Ser1177 (1:500, Abcam), NOX-2 (1:2000, Abcam), NOX-4 (1:500, Abcam), and GAPDH (1:10,000, Ambion) were used. The membranes were developed with an enhanced chemiluminescence detection system and exposed on X-ray films.

Reactive oxygen species (ROS) determination

ROS measurement in en face endothelium and cross-sectional area of rat aortae was performed as described [16, 17]. Some aortae were freshly prepared for en face staining of ROS. Some aortae were embedded in OCT compound (Tissue-Tek), frozen in liquid nitrogen, and then cut into sections of 10-µm thickness on cryostat (Shandon). Fresh aortae or frozen sections of aortae were incubated for 20 min in 5 µM dihydroethidium (DHE; Molecular Probes)-containing PBS at 37 °C. Fluorescence was observed by Fluoview FV1000 laser scanning confocal system (Olympus, Tokyo, Japan; 515-nm excitation; 585-nm long-pass filter). DHE fluorescence intensity was analyzed by Fluoview FV10-ASW1.5 software. For each section, a square region with an area of 80 μm × 80 μm was selected for analysis. The summarized data represent the fold change in fluorescence intensity relative to that in control rat aortae [14].

Determination of cGMP content

The concentrations of cGMP were measured using a commercial ELISA kit (Enzo Life Sciences, Inc. USA) as described before [18]. Aortae from sham control, OVX, BT-treated and E2-treated rats were incubated in a O2-saturated Krebs’ solution at 37 °C for 60 min and then exposed to 0.3 μM phenylephrine for 10 min and then to 1 μM ACh for 1 min. The aortae were removed, and the cGMP concentrations were determined.

Drugs and chemicals

Phe, ACh, L-NAME, ODQ and SNP were purchased from Sigma-Aldrich. Stocks of drugs were kept at −20 °C.

Data analysis

The relaxations were expressed as percentage reduction in Phe-induced contraction. The vasorelaxing effect was expressed as percentage reduction in evoked contraction. Concentration–relaxation curves were analyzed by nonlinear regression curve fitting using GraphPad Prism software (version 5.0) to estimate Emax as the maximal response and pD2 as the negative logarithm of the drug concentration that produced 50 % of Emax. In order to demonstrate the contribution of endothelial NO to Phe-induced tone, the first concentration–response curve (control) was subtracted from the second concentration–response curve (after inhibition of NO/cyclic GMP-dependent dilation) at individual concentrations for each ring. The amount of L-NAME or ODQ tone was compared among experimental groups as an index of the influence of basal NO. Data represent mean ± S.E.M. of rings from n animals. Concentration–response curves were analyzed by two-way ANOVA followed by Bonferroni post hoc tests. P < 0.05 indicates significant difference. For protein expression, the protein of interest was normalized to GAPDH and then expressed relative to control. Statistical significances of flow-mediated dilatation, protein of interest, and ROS measurement (Figs. 4, 5, and 6 respectively) were determined by one-way analysis of variance followed by Bonferroni’s multiple comparison test. Values of P < 0.05 were considered statistically significant.

Results

Chronic black tea consumption improved cholesterol profiles in OVX rats

17β-Estradiol serum levels were reduced in OVX rats compared with sham-operated control rats. However, chronic BT treatment did not significantly affect 17β-estradiol serum levels in OVX rats. Uterine weight decreased markedly in OVX rats, which was reversed by E2 treatment, while black tea consumption had no effects (Table 1). Body weight of OVX rats was increased, which was partially reversed by E2 treatment, but unaffected by chronic BT treatment. The ratio of heart weight over body weight was in OVX was decreased, but significantly increased in BT-treated and E2-treated groups. The OVX rats had higher serum levels of total cholesterol, triacylglycerols, HDL, non-HDL, and the non-HDL/HDL ratio than age-matched control rats. BT treatment modified the lipid profile in OVX rats through lowering total cholesterol, triglyceride, and HDL-C, while E2 treatment only affected total cholesterol and HDL-C. Both BT and E2 treatments did not change the non-HDL/HDL ratio in OVX rats.
Table 1
Serum 17β-estradiol levels, aortic cyclic GMP (cGMP) concentration, serum lipid profiles, body weight (BW), heart weight (HW), and uterine weight (UW) of control, OVX rats, and OVX rats receiving administration of black tea (OVX + BT) or estrogen treatment (OVX + E2)
Parameters
Control
OVX
OVX + BT
OVX + E2
17β-Estradiol (pg/mL)
52.3 ± 7.3
7.9 ± 2.3a,***
10.1 ± 3.7a,***
38.2 ± 2.8b,***; c,***
cGMP (pmol/mg protein)
2.65 ± 0.33
0.89 ± 0.15a,***
2.11 ± 0.41b,*
2.68 ± 0.69b,*
Total cholesterol (mg/dL)
78.87 ± 2.16
112.50 ± 4.04a,***
98.45 ± 1.50 a,***; b,**
96.48 ± 4.59a,**; b,*
Triglyceride (mg/dL)
55.89 ± 3.00
79.33 ± 8.93a,*
42.95 ± 1.53a,**; b,**
66.31 ± 7.13c,**
HDL-C (mg/dL)
56.02 ± 1.82
74.72 ± 2.98a,***
66.27 ± 0.59a,***; b,*
46.2 ± 2.56a,*; b,***; c,***
Non-HDL-C (mg/dL)
21.02 ± 1.50
38.43 ± 5.69a,*
32.87 ± 2.39a,**
39.49 ± 4.08a,**
Non-HDL-C:HDL
0.27 ± 0.02
0.58 ± 0.09a,**
0.50 ± 0.05a,**
0.48 ± 0.05a,**
BW (g)
255.6 ± 1.8
346.1 ± 7.5a,***
336.1 ± 3.7a,***
280.6 ± 5.5a,***; b,***; c,***
HW (g)
1.07 ± 0.02
1.09 ± 0.02
1.14 ± 0.03
1.06 ± 0.02c,***
% HW/BW
0.43 ± 0.01
0.31 ± 0.02a,***
0.38 ± 0.01a,**; b,**
0.39 ± 0.01a,*; b,**
UW (g)
0.67 ± 0.02
0.11 ± 0.04a,***
0.10 ± 0.01a,***
0.330 ± 0.03a,***; b,***; c,***
UW/BW
0.26 ± 0.01
0.02 ± 0.00a,***
0.03 ± 0.00a,***
0.12 ± 0.01a,***; b,***; c,***
Results are mean ± SEM of 6–9 rats. Statistical significance versus control (a), versus OVX (b) or versus OVX + BT (c) is indicated by * P < 0.05, ** P < 0.005 and *** P < 0.001
BT or estrogen treatment reduced phenylephrine-induced contraction through an increase in NO bioavailability treatment with L-NAME (100 μM) enhanced Phe-induced contractions in aortic rings with endothelium from all groups. Aortic rings from control (Fig. 1a), BT-treated (Fig. 1c) and E2-treated OVX rats (Fig. 1d) exhibited a greater augmentation of the Phe-induced contraction after inhibition of NO synthase compared with those from OVX rats (Fig. 1b). The Phe-induced contraction was greater in aortae from OVX rats when compared with control and BT/E2-treated rats (1st CRC: Emax: 0.66 ± 0.07 g/mg dry weight in control, 1.29 ± 0.1 g/mg dry weight in OVX, 0.54 ± 0.06 g/mg dry weight in OVX + BT, 0.69 ± 0.04 g/mg dry weight in OVX + E2, n = 7, P < 0.0001). After L-NAME treatment, there are significant differences in the Emax for Phe on aortas from OVX rats when compared with control and BT-treated rats only, not in E2-treated rats (2nd CRC: Emax: 1.26 ± 0.12 g/mg dry weight in control, 1.61 ± 0.09 g/mg dry weight in OVX, 1.28 ± 0.07 g/mg dry weight in OVX + BT, 1.47 ± 0.1 g/mg dry weight in OVX + E2, n = 7, P < 0.05). No differences in pD2 values were found among control, OVX, OVX + BT and OVX + E2. The L-NAME-sensitive tone was higher in rings in control and BT- or E2-treated OVX rats than that in OVX rats (Fig. 1e).
Likewise, treatment with ODQ (3 μM, an inhibitor of NO-dependent soluble guanylate cyclase) was less effective in enhancing the Phe-induced responses in rings from OVX rats (Fig. 2b) compared with those from control (Fig. 2a) or BT- or E2-treated OVX rats (Fig. 2c, d). The ODQ-sensitive tone was higher in aortae in control and BT- or E2-treated OVX rats than those in non-treated OVX rats (Fig. 2e). Further, cGMP levels after ACh stimulation were reduced in the aortae from OVX rats compared with those from control rats. ACh-stimulated cGMP production was significantly increased in the aortas from BT- and E2-treated rats compared with those from OVX rats (Table 1).

Black tea treatment improved endothelial functions in OVX rats

Ovariectomy significantly impaired the acetylcholine-induced maximal relaxation in aortae (Emax: 68.2. ± 8.53 %, P < 0.05 compared to 84.7 ± 9.48 % obtained in control rats). EDRs in response to accumulative concentration of ACh in Phe-precontracted segments of aortae were improved by BT and E2 treatments in OVX rats (Emax: 68.2 ± 8.53 % in OVX, 81.8 ± 7.45 % in OVX + BT, 82.5 ± 13.61 % in OVX + E2, n = 9, P < 0.0001) (Fig. 3a) without affecting the SNP-induced relaxations (Fig. 3c). On the other hand, no differences in pD2 values were found among control, OVX, OVX + BT and OVX + E2 aortas (7.91 ± 0.12; 8.06 ± 0.13; 8.14 ± 0.21; 8.15 ± 0.19, respectively).
Likewise, ovariectomy significantly impaired the ACh-induced maximal relaxation in renal arteries (Emax: 34.4 ± 1.5 %, P < 0.05 compared to 73.7 ± 1.8 % obtained in control rats). BT and E2 treatments improved EDRs in renal arteries (Emax: 34.4 ± 1.5 % in OVX, 66.7 ± 2.0 % in OVX + BT, 77.9 ± 1.7 % in OVX + E2, n = 9, P < 0.0001; Fig. 3b). There was no difference in pD2 values were found among control, OVX, OVX + BT and OVX + E in renal arteries (7.02 ± 0.14; 6.78 ± 0.23; 6.89 ± 0.11; 6.73 ± 0.16, respectively). The flow-induced relaxations in third order of mesenteric arteries were also improved significantly by BT and E2 treatments in OVX rats (Fig. 4a, b & c).

Black tea consumption increased phosphorylated eNOS and reduced NAD(P)H oxidase-mediated oxidative stress

Chronic BT treatment to OVX rats augmented the phosphorylation of eNOS (Fig. 5a) without altering the total eNOS (Fig. 5b). Western blotting results showed that BT treatment reversed the elevated protein levels of membrane-bound NAD(P)H oxidase subunits, NOX2 (Fig. 5c) and NOX4 in aortae of OVX rats (Fig. 5d).

Black tea attenuated ROS production in vivo

Elevation in ROS levels was reduced following BT and E2 treatment in aortae (both en face endothelium and cross-sectional area) from OVX rats (Fig. 6).

Discussion

The present study demonstrates that a 4-week treatment with BT restores the impaired EDRs in renal arteries and aortae of OVT rats. The flow-mediated dilatations in the third-order mesenteric arteries were also augmented in OVX rats receiving BT treatment. These effects are likely associated with an increase in NO bioavailability. We showed for the first time that black tea treatment reduces oxidative stress in aortas of OVX rats, which is associated with the inhibition of NAD(P)H oxidase. The elevated production of ROS, especially superoxide anions is known to inactivate NO, thus to impair endothelial function. Taken together, the present study reveals that black tea has the potential to induce endothelial adaptations similar to estrogen, primarily those involving NO availability probably inhibiting oxidative stress in estrogen deficiency without affecting estrogen level.
The clinical importance of the endothelial NO pathway is well documented. Endothelial dysfunction, showed as reduced NO levels, is one of the most common pathological changes in cardiovascular diseases and is revealed by impaired endothelium-dependent vasodilatation or by enhanced vasoconstriction [19]. Both human and animal studies suggest diminished NO bioactivity after menopause [20]. NO is derived from its precursor, l-arginine, and its synthesis can be blocked by l-arginine analogues, such as L-NAME. Once released from the endothelial cells, NO diffuses toward the underlying vascular smooth muscle cells and stimulates the cyclic GMP-dependent pathway leading to relaxation that is sensitive to ODQ (an inhibitor of soluble guanylate cyclase). Therefore, the differences in basal NO release can be determined indirectly by differences in the contractile responses to a vasoconstrictor before and after treatment with L-NAME or ODQ. The present study demonstrated that aortae from control or BT-treated and E2-treated OVX rats exhibited a greater potentiation of phenylephrine-evoked contractions in the presence of L-NAME (Fig. 1) or ODQ (Fig. 2) as compared with OVX rats. The present data indicate that the basal release of NO is augmented significantly in OVX rats receiving BT and E2 treatment.
Indeed, ingestion of BT led to significant increments in brachial artery flow-mediated, i.e., NO-mediated, dilation (FMD). Duffy et al. [21] also demonstrated that both acute and prolonged black tea ingestion significantly improved FMD in patients with coronary artery disease [21]. The beneficial effects of tea on FMD were clearly related to significant increments in plasma flavonoid concentration, thereby strongly supporting the conclusion that black tea consumption markedly improved NO bioavailability in vivo because of its high flavonoid content. In a randomized controlled parallel study, Hodgson et al. [22] showed a significant and consistent increase in endothelium-dependent vasodilation after regular consumption of 5 cups/day (250 mL each) of black tea, given over a period of 4 week in mildly dyslipidemic subjects. The present study suggests that BT and E2 treatment is highly effective to reverse endothelial dysfunction in conduit arteries such as aortae and renal arteries (Fig. 3) and the flow-mediated dilatation in small resistance mesenteric arteries (Fig. 4) of OVX rats. The results of this study suggest that black tea has comparable effects to estrogen treatment in restoring NO availability and, in a similar way, the endothelial dysfunction observed in the animal model of estrogen deficiency.
An improved contribution of the NO pathway following BT treatment may involve either stimulation of eNOS activity or greater expression of the eNOS protein. The present finding showed that BT treatment failed to affect the expression of eNOS protein, however, induced the phosphorylation of eNOS (Fig. 5a, b). In addition, the increase in NO bioavailability might be attributed to the reduction in ROS production. Accumulative evidences suggested that ROS production during estrogen deprivation may lead to the development of endothelial dysfunction [2325], especially those ROS derived from NADPH oxidase, which is the main source of superoxide anion in the vascular system [26]. The present results suggest that BT and E2 treatment suppressed the expression of NADPH oxidase such as NOX-2 and NOX-4 (Fig. 5c, d) and thereby reduced the oxidative stress in vascular wall of OVX rats (Fig. 6). Taken together, the present novel finding reveals that black tea improves endothelial function in the same way as estrogen through inhibiting oxidative stress and increasing NO bioavailability in OVX rats.
The cholesterol levels are generally high in postmenopausal women [27]. In the present experiment, ovariectomy resulted in an increase in total and HDL cholesterol, which was reversed by estrogen treatment in line with the findings in previous studies [14, 28]. Estrogen therapy is shown to induce favorable changes in plasma lipid profiles [29]. Although HDL is generally recognized as beneficial to endothelial function, the effect of estrogen may be partially due to reduced total cholesterol level which is not related to modulation of HDL level. A clinical trial by Davies et al. [30] demonstrated that daily inclusion of black tea reduces total cholesterol level significantly in mildly hypercholesterolemic adults and, therefore, minimizes the risk of coronary heart disease. We also present evidence supporting the effectiveness of black tea and estrogen treatments in modulating the lipid profiles in an estrogen deficient state OVX rats (Table 1). These findings may have important implications for the treatment of postmenopausal cardiovascular complications.
In conclusion, the present study indicates that chronic oral administration with black tea, similar to E2 treatment. Improved NO bioavailability accompanied by the reduced ROS production through the down-regulation of the expression of NADPH oxidase. The present data suggest that postmenopausal women can benefit from regular black tea consumption, probably counteracting the development of cardiovascular and metabolic abnormalities related to the rise in the level of the cholesterol level.

Acknowledgments

This study was supported by Hong Kong General Research Fund (260712).

Author contribution statement

Fung Ping Leung, Lai Ming Yung, Ngai Ching Yuen, Wai San Cheang, Xiao Yu Tian, Chi Wai Lau, Yang Zhang and Jian Liu performed the experiments and analyzed the data. Fung Ping Leung and Ngai Ching Yuen made the figures and tables. Yu Huang, Zhen Yu Chen, Zhao-Xiang Bian and Xiaoqiang Yao designed the study and prepared the manuscript.

Compliance with ethical standards

Conflict of interest

The author(s) declare no competing financial interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

Neuer Inhalt

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Literatur
1.
Zurück zum Zitat Barrett-Connor E, Bush TL (1991) Estrogen and coronary heart disease in women. JAMA 265:1861–1867CrossRef Barrett-Connor E, Bush TL (1991) Estrogen and coronary heart disease in women. JAMA 265:1861–1867CrossRef
2.
Zurück zum Zitat Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1991) Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med 325:756–762CrossRef Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1991) Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med 325:756–762CrossRef
3.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059CrossRef
4.
Zurück zum Zitat Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427CrossRef Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427CrossRef
5.
Zurück zum Zitat Paganini-Hill A, Ross RK, Henderson BE (1988) Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 297:519–522CrossRef Paganini-Hill A, Ross RK, Henderson BE (1988) Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 297:519–522CrossRef
6.
Zurück zum Zitat Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605–613CrossRef Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605–613CrossRef
7.
Zurück zum Zitat Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRef Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRef
8.
Zurück zum Zitat Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Committee Women’s Health Initiative Steering (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712CrossRef Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Committee Women’s Health Initiative Steering (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712CrossRef
9.
Zurück zum Zitat Hodgson JM, Croft KD (2010) Tea flavonoids and cardiovascular health. Mol Asp Med 31:495–502CrossRef Hodgson JM, Croft KD (2010) Tea flavonoids and cardiovascular health. Mol Asp Med 31:495–502CrossRef
10.
Zurück zum Zitat Grassi D, Aggio A, Onori L, Croce G, Tiberti S, Ferri C, Ferri L, Desideri G (2008) Tea, flavonoids, and nitric oxide-mediated vascular reactivity. J Nutr 138:1554S–1560S Grassi D, Aggio A, Onori L, Croce G, Tiberti S, Ferri C, Ferri L, Desideri G (2008) Tea, flavonoids, and nitric oxide-mediated vascular reactivity. J Nutr 138:1554S–1560S
11.
Zurück zum Zitat Yung LM, Leung FP, Wong WT, Tian XY, Yung LH, Chen ZY, Yao XQ, Huang Y (2008) Tea polyphenols benefit vascular function. Inflammopharmacology 16:230–234CrossRef Yung LM, Leung FP, Wong WT, Tian XY, Yung LH, Chen ZY, Yao XQ, Huang Y (2008) Tea polyphenols benefit vascular function. Inflammopharmacology 16:230–234CrossRef
12.
Zurück zum Zitat Arab L, Liebeskind DS (2010) Tea, flavonoids and stroke in man and mouse. Arch Biochem Biophys 501:31–36CrossRef Arab L, Liebeskind DS (2010) Tea, flavonoids and stroke in man and mouse. Arch Biochem Biophys 501:31–36CrossRef
13.
Zurück zum Zitat Lorenz M, Urban J, Engelhardt U, Baumann G, Stangl K, Stangl V (2009) Green and black tea are equally potent stimuli of NO production and vasodilation: new insights into tea ingredients involved. Basic Res Cardiol 104:100–110CrossRef Lorenz M, Urban J, Engelhardt U, Baumann G, Stangl K, Stangl V (2009) Green and black tea are equally potent stimuli of NO production and vasodilation: new insights into tea ingredients involved. Basic Res Cardiol 104:100–110CrossRef
14.
Zurück zum Zitat Yung LM, Tian XY, Wong WT, Leung FP, Yung LH, Chen ZY, Lau CW, Vanhoutte PM, Yao X, Huang Y (2013) Chronic cranberry juice consumption restores cholesterol profiles and improves endothelial function in ovariectomized rats. Eur J Nutr 52:1145–1155CrossRef Yung LM, Tian XY, Wong WT, Leung FP, Yung LH, Chen ZY, Lau CW, Vanhoutte PM, Yao X, Huang Y (2013) Chronic cranberry juice consumption restores cholesterol profiles and improves endothelial function in ovariectomized rats. Eur J Nutr 52:1145–1155CrossRef
15.
Zurück zum Zitat Tian XY, Wong WT, Xu A, Lu Y, Zhang Y, Wang L, Cheang WS, Wang Y, Yao X, Huang Y (2012) Uncoupling protein-2 protects endothelial function in diet-induced obese mice. Circ Res 110:1211–1216CrossRef Tian XY, Wong WT, Xu A, Lu Y, Zhang Y, Wang L, Cheang WS, Wang Y, Yao X, Huang Y (2012) Uncoupling protein-2 protects endothelial function in diet-induced obese mice. Circ Res 110:1211–1216CrossRef
16.
Zurück zum Zitat Cheang WS, Tian XY, Wong WT, Lau CW, Lee SS, Chen ZY, Yao X, Wang N, Huang Y (2014) Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5′ adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway. Arterioscler Thromb Vasc Biol 34:830–836CrossRef Cheang WS, Tian XY, Wong WT, Lau CW, Lee SS, Chen ZY, Yao X, Wang N, Huang Y (2014) Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5′ adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway. Arterioscler Thromb Vasc Biol 34:830–836CrossRef
17.
Zurück zum Zitat Zhang Y, Liu J, Tian XY, Wong WT, Chen Y, Wang L, Luo J, Cheang WS, Lau CW, Kwan KM, Wang N, Yao X, Huang Y (2014) Inhibition of bone morphogenic protein 4 restores endothelial function in db/db diabetic mice. Arterioscler Thromb Vasc Biol 34:152–159CrossRef Zhang Y, Liu J, Tian XY, Wong WT, Chen Y, Wang L, Luo J, Cheang WS, Lau CW, Kwan KM, Wang N, Yao X, Huang Y (2014) Inhibition of bone morphogenic protein 4 restores endothelial function in db/db diabetic mice. Arterioscler Thromb Vasc Biol 34:152–159CrossRef
18.
Zurück zum Zitat Huang Y, Wong CM, Lau CW, Yao X, Tsang SY, Su YL, Chen ZY (2004) Inhibition of nitric oxide/cyclic GMP-mediated relaxation by purified flavonoids, baicalin and baicalein, in rat aortic rings. Biochem Pharmacol 67(4):787–794CrossRef Huang Y, Wong CM, Lau CW, Yao X, Tsang SY, Su YL, Chen ZY (2004) Inhibition of nitric oxide/cyclic GMP-mediated relaxation by purified flavonoids, baicalin and baicalein, in rat aortic rings. Biochem Pharmacol 67(4):787–794CrossRef
19.
Zurück zum Zitat Wong WT, Wong SL, Tian XT, Huang Y (2010) Endothelial dysfunction: the common consequence in diabetes and hypertension. J Cardiovasc Pharmacol 55:300–307CrossRef Wong WT, Wong SL, Tian XT, Huang Y (2010) Endothelial dysfunction: the common consequence in diabetes and hypertension. J Cardiovasc Pharmacol 55:300–307CrossRef
20.
Zurück zum Zitat Ganz P (2002) Vasomotor and vascular effects of hormone replacement therapy. Am J Cardiol 90:11F–16FCrossRef Ganz P (2002) Vasomotor and vascular effects of hormone replacement therapy. Am J Cardiol 90:11F–16FCrossRef
21.
Zurück zum Zitat Duffy SJ, Keaney JF Jr, Holbrook M, Gokce N, Swerdloff PL, Frei B, Vita JA (2001) Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 104:151–156CrossRef Duffy SJ, Keaney JF Jr, Holbrook M, Gokce N, Swerdloff PL, Frei B, Vita JA (2001) Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 104:151–156CrossRef
22.
Zurück zum Zitat Hodgson JM, Puddey IB, Burke V, Watts GF, Beilin LJ (2002) Regular ingestion of black tea improves brachial artery vasodilator function. Clin Sci (Lond) 102:195–201CrossRef Hodgson JM, Puddey IB, Burke V, Watts GF, Beilin LJ (2002) Regular ingestion of black tea improves brachial artery vasodilator function. Clin Sci (Lond) 102:195–201CrossRef
23.
Zurück zum Zitat Yung LM, Wong WT, Tian XY, Leung FP, Yung LH, Chen ZY, Yao X, Lau CW, Huang Y (2011) Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats. PLoS One 6:e17437CrossRef Yung LM, Wong WT, Tian XY, Leung FP, Yung LH, Chen ZY, Yao X, Lau CW, Huang Y (2011) Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats. PLoS One 6:e17437CrossRef
24.
Zurück zum Zitat Caliman IF, Lamas AZ, Dalpiaz PL, MedeirosAR Abreu GR, Figueiredo SG, Gusmão LN, Andrade TU, Bissoli NS (2013) Endothelial relaxation mechanisms and oxidative stress are restored by atorvastatin therapy in ovariectomized rats. PLoS One 8:e80892CrossRef Caliman IF, Lamas AZ, Dalpiaz PL, MedeirosAR Abreu GR, Figueiredo SG, Gusmão LN, Andrade TU, Bissoli NS (2013) Endothelial relaxation mechanisms and oxidative stress are restored by atorvastatin therapy in ovariectomized rats. PLoS One 8:e80892CrossRef
25.
Zurück zum Zitat Virdis A, Ghiadoni L, Pinto S, Lombardo M, Petraglia F, Gennazzani A, Buralli S (2000) Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation 101:2258–2263CrossRef Virdis A, Ghiadoni L, Pinto S, Lombardo M, Petraglia F, Gennazzani A, Buralli S (2000) Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation 101:2258–2263CrossRef
26.
Zurück zum Zitat Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87:840–844CrossRef Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87:840–844CrossRef
27.
Zurück zum Zitat Lobo RA (1990) Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 75(Suppl):18S–25S Lobo RA (1990) Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 75(Suppl):18S–25S
28.
Zurück zum Zitat Kushwaha RS, Lewis DS, Carey KD, McGill HC Jr (1991) Effects of estrogen and progesterone on plasma lipoproteins and experimental atherosclerosis in the baboon (Papio sp.). Arterioscler Thromb 11(1):23–31CrossRef Kushwaha RS, Lewis DS, Carey KD, McGill HC Jr (1991) Effects of estrogen and progesterone on plasma lipoproteins and experimental atherosclerosis in the baboon (Papio sp.). Arterioscler Thromb 11(1):23–31CrossRef
29.
Zurück zum Zitat Subbiah MT (1998) Mechanisms of cardioprotection by estrogens. Proc Soc Exper Biol Med 217:23–29CrossRef Subbiah MT (1998) Mechanisms of cardioprotection by estrogens. Proc Soc Exper Biol Med 217:23–29CrossRef
30.
Zurück zum Zitat Davies MJ, Judd JT, Baer DJ, Clevidence BA, Paul DR, Edwards AJ, Wiseman SA, Muesing RA, Chen SC (2003) Black tea consumption reduces total and LDL cholesterol in mildly hypercholesterolemic adults. J Nutr 133(10):3298S–3302S Davies MJ, Judd JT, Baer DJ, Clevidence BA, Paul DR, Edwards AJ, Wiseman SA, Muesing RA, Chen SC (2003) Black tea consumption reduces total and LDL cholesterol in mildly hypercholesterolemic adults. J Nutr 133(10):3298S–3302S
Metadaten
Titel
Chronic black tea extract consumption improves endothelial function in ovariectomized rats
verfasst von
Fung Ping Leung
Lai Ming Yung
Ching Yuen Ngai
Wai San Cheang
Xiao Yu Tian
Chi Wai Lau
Yang Zhang
Jian Liu
Zhen Yu Chen
Zhao-Xiang Bian
Xiaoqiang Yao
Yu Huang
Publikationsdatum
15.08.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nutrition / Ausgabe 5/2016
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-015-1012-0

Weitere Artikel der Ausgabe 5/2016

European Journal of Nutrition 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.